These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1051 related articles for article (PubMed ID: 19636000)
1. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
3. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
4. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
5. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study. Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184 [TBL] [Abstract][Full Text] [Related]
6. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation. Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161 [TBL] [Abstract][Full Text] [Related]
10. IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas. Kramář F; Minárik M; Benešová L; Halková T; Netuka D; Bradáč O; Beneš V Folia Biol (Praha); 2016; 62(5):194-202. PubMed ID: 27978414 [TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094 [TBL] [Abstract][Full Text] [Related]
12. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028 [TBL] [Abstract][Full Text] [Related]
13. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690 [TBL] [Abstract][Full Text] [Related]
14. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602 [TBL] [Abstract][Full Text] [Related]
15. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781 [TBL] [Abstract][Full Text] [Related]
17. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062 [TBL] [Abstract][Full Text] [Related]
19. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents. Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620 [TBL] [Abstract][Full Text] [Related]
20. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M; Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]